retatrutide triple agonist glp-1 gip glucagon phase 3 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ ✨ Retatrutide: The Next Evolution

Each one delivers high-protein, macro-complete smoothies packed with healthy fats, vitamin B12, fibre, and antioxidants

A Danish nationwide registry study, including 116,699 individuals with type 2 diabetes and 116,008 matched controls without diabetes, revealed that treatment with GLP-1 RAs was associated with a lower risk of depression [16]

doi: 10.1371/journal.pmed.1002482 66 VeitchD

It also helps regenerate enzymes that keep your metabolism running smoothly

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes

Real-world treatment gaps are expected to make follow-up support more visible